Financial Reports

OncoZenge is developing BupiZenge, a lozenge based on the safe and effective, non-opioid long-acting pain reliever bupivacaine. BupiZenge’s primary indication is oral mucositis and it has the potential to help millions of people with their oral pain caused by radiotherapy and chemotherapy